Sodium-glucose cotransporter 2, or SGLT2, inhibitors and glucagon-like peptide-1 receptor agonists lowered the risk for COPD exacerbation in adults with the disease and type 2 diabetes, researchers ...

Learn about the financial strain caused by the skyrocketing demand and costs of GLP-1 drugs, and how health plans and providers are struggling to balance it.

These and other GLP1-RA diabetes/weight-loss meds can also boost outcomes for folks battling chronic kidney disease, new ...

Compounding pharmacies aren’t the only makers of off-brand versions of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. The ...

Ozempic, Wegovy, Saxenda, Trulicity: These and other GLP1-RA diabetes/weight-loss meds can also boost outcomes for fo ...

There's growing evidence to suggest that GLP-1 drugs, which include Ozempic's semaglutide, may be useful for treating alcohol ...

Women prescribed a GLP-1 receptor agonist up to 2 years before conception were less likely to develop hypertensive disorders ...

As many as 40% of Americans are obese, putting them at an increased risk for high blood pressure, diabetes, stroke, heart disease and certain cancers, according to the CDC.

Low-fat diets are problematic, says world-renowned internist and regenerative physician Michael Aziz, MD, author of the ...

In obesity, Lilly removed a dual amylin calcitonin receptor agonist (DACRA) from its phase 1 pipeline. Lilly got into DACRAs by partnering with KeyBioscience in 2017. At one time, the Big Pharma was ...

If you’re in a calorie deficit – either from dieting or while taking a weight loss drug – these exercises help direct your ...